TABLE 2.
Baseline clinical characteristics of study participantsa
| Characteristic | Total Sample (n=295) |
Incident Arm Swelling (n=27) |
No Incident Arm Swelling (n=268) |
P |
|---|---|---|---|---|
| BMI — kg/m2 | 29.2±6.1 | 29.0±5.9 | 29.2±6.1 | 0.74 |
| Cancer stage — no. (%) | 0.55 | |||
| Ductal in situ | 1 (1%) | 1 (4%) | 0 (0%) | |
| 1 | 143 (48%) | 6 (22%) | 137 (51%) | |
| 2 | 15 (5%) | 8 (30%) | 7 (3%) | |
| 3 | 97 (33%) | 1 (4%) | 96 (36%) | |
| Unknown | 39 (13%) | 11 (41%) | 28 (10%) | |
| No. of nodes removed | 11.7±7.9 | 9.3±8.3 | 11.9±8.0 | 0.05 |
| Chemotherapy — no. (%) | 220 (76%) | 22 (81%) | 198 (74%) | 0.58 |
| Radiation — no. (%) | 229 (78%) | 16 (59%) | 213 (79%) | 0.005 |
| Current receipt of drugs — no. % | ||||
| Tamoxifen | 69 (23%) | 3 (11%) | 66 (25%) | 0.27 |
| Aromatase inhibitor | 2 (<1%) | 0 (0%) | 2 (<1%) | 0.80 |
| Months since cancer diagnosis | 61.6±29.4 | 54.6±31.1 | 61.2±40.1 | 0.39 |
| Lymphedema Diagnosis — no. (%) | 0.09 | |||
| With lymphedema | 141 (48%) | 10 (37%) | 131 (49%) | |
| At-Risk for lymphedema | 154 (52%) | 17 (63%) | 137 (51%) | |
| Common Toxicity Criteria lymphedema grade – no. (%)b |
0.14 | |||
| 0 | 12 (9%) | 3 (30%) | 9 (7%) | |
| 1 | 30 (21%) | 2 (20%) | 28 (21%) | |
| 2 | 58 (41%) | 3 (30%) | 55 (42%) | |
| 3 | 41 (29%) | 2 (20%) | 39 (30%) | |
| Hypertension | 86 (29%) | 9 (33%) | 77 (29%) | 0.66 |
| Diabetes | 30 (10%) | 3 (11%) | 27 (10%) | 0.74 |
a
Plus-minus values are means ±SD. Percentage may not sum to 100% due to rounding error
b
Among the 141 women with lymphedema.